CAMBRIDGE, Mass., May 23, 2016 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that John E. Bishop, Ph.D. has joined the company as senior vice president of pharmaceutical sciences.
“I am delighted to welcome John to Genocea at such an exciting time for the company as we progress GEN-003, our immunotherapy for genital herpes, towards expected Phase 3 initiation next year and continue to advance our research and preclinical programs in immuno-oncology and infectious diseases,” said Chip Clark, president and chief executive officer of Genocea. “John’s experience in successfully building teams to support pharmaceutical sciences and manufacturing activities for all stages of product development and commercialization will be incredibly valuable to Genocea.”
Dr. Bishop brings a wealth of experience in process development, formulation, quality, and supply chain management across diverse product platforms, ranging from small molecules to complex proteins. Prior to joining Genocea, Dr. Bishop was senior vice president of pharmaceutical sciences at Momenta Pharmaceuticals, Inc., where he worked since 2004 and was responsible for all aspects of chemistry, manufacturing, and controls across an array of development and commercial-stage products. Prior to Momenta, he spent a combined 13 years in various roles of increasing responsibility at Millennium Pharmaceuticals, DuPont Pharmaceuticals, and Alcon Laboratories. Dr. Bishop holds a Ph.D. in Organic Chemistry from the University of California, Berkeley, an M.B.A. from Northeastern University, and a B.S. in Chemistry and German from Tufts University.
Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. T cells are increasingly recognized as a critical element of protective immune responses to a wide range of diseases, but traditional discovery methods have proven unable to identify the targets of such protective immune response. Using ATLAS, its proprietary technology platform, Genocea identifies these targets to potentially enable the rapid development of medicines to address critical patient needs. Genocea's pipeline of novel clinical stage T cell-enabled product candidates includes GEN-003 for genital herpes, GEN-004 for the prevention of infection by all serotypes of pneumococcus (development suspended pending further data analysis and consultation with our advisers), and earlier-stage programs in chlamydia, genital herpes prophylaxis, malaria and cancer immunotherapy. For more information, please visit the company's website at www.genocea.com.